Five women died after receiving counterfeit oxytocin injections during C-section deliveries at a government hospital in Kota, Rajasthan [1].
The tragedy highlights critical failures in pharmaceutical quality control and the lethal consequences of counterfeit medicine in public health settings. Because the injections lacked active ingredients, medical staff were unable to stop postpartum hemorrhages, leading to the fatalities.
The deaths occurred over a span of 13 days in May 2026 [3, 4]. According to laboratory tests, the oxytocin batch contained zero active drug and consisted of water only [2, 3]. This lack of potency meant the drug could not induce the uterine contractions necessary to prevent excessive bleeding after surgery [2, 3].
The implicated batch was manufactured by Jackson Laboratories Pvt Ltd, based in Amritsar [1]. Following the deaths, Rajasthan authorities banned the specific drug batch after samples failed potency tests [1].
Medical reports indicate the women suffered severe complications before dying hours after their deliveries. These complications included kidney failure, a collapse of platelets, and a crash in blood pressure [2].
Authorities are currently investigating the supply chain to determine how the counterfeit product entered the government hospital. The incident has prompted a wider review of drug procurement, and testing protocols for critical maternal health medications in the region [1, 5].
“The oxytocin batch contained zero active drug and consisted of water only.”
This incident underscores the vulnerability of government medical supply chains to counterfeit pharmaceuticals. Oxytocin is a critical, life-saving intervention for postpartum hemorrhage; when the drug is replaced by an inert substance like water, doctors are left without the primary tool to prevent maternal mortality, turning a manageable surgical risk into a fatal event.
